Form 4: Johanna Mercier Receives RSU Grant at Neurocrine

Director Johanna Mercier was granted 2,567 restricted stock units by Neurocrine Biosciences, Inc. vesting in May 2027.

Summary

• Director Johanna Mercier acquired 2,567 Restricted Stock Units (RSUs) on May 27, 2026.
• Each RSU represents a contingent right to receive one share of Neurocrine Biosciences common stock.
• The grant has a zero-dollar exercise price.
• The units are scheduled to vest in full on May 27, 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial health.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified; this is a standard equity compensation grant for a board member.

Risks

• None identified; this is a standard equity compensation grant for a board member.

Future Outlook

The RSUs will vest in full on May 27, 2027, at which point the director will receive common stock.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practices in the biotechnology sector to ensure director retention and alignment with long-term performance goals.

Comparison to Industry Standards

• The grant of RSUs to non-employee directors is consistent with standard compensation packages for mid-to-large cap biotechnology companies.
• The one-year cliff vesting schedule is a common practice for annual director equity awards.

Stakeholder Impact

• Minimal impact on shareholders; represents standard director compensation.

Next Steps

• Vesting of the 2,567 RSUs on May 27, 2027.

Key Dates

Keywords

Neurocrine Biosciences, NBIX, Form 4, Insider Trading, Restricted Stock Units, Director Compensation